脑利钠肽与心力衰竭的研究进展

中国临床药理学与治疗学 ›› 2004, Vol. 9 ›› Issue (1): 8-12.

脑利钠肽与心力衰竭的研究进展

陈协兴综述, 洪华山, 王一波审校

福建医科大学附属协和医院心内科, 福建省冠心病研究所, 福州 350001, 福建

收稿日期:2003-09-01 修回日期:2003-10-12 出版日期:2004-01-26 发布日期:2020-11-16
通讯作者: 洪华山,男, 医学博士, 副教授, 硕士生导师, 研究方向:冠心病及其心肌纤维化的临床与基础研究。Tel:0591-3357896-8455 8475 E-mail: honghuashan@hotmail.com
作者简介:陈协兴, 男, 医学硕士, 主治医师, 从事心血管病临床与基础研究。Tel:0591-3357896-8422 8475 E-mail: chenxiexing@medmail.com.cn

Progress in research of brain natriuretic peptide and heart failure

CHEN Xie-Xing, HONG Hua-Shan, WANG Yi-Bo

Department of Cardiology, Union Hospital of Fujian Medical University, Institute of Coronary Heart Disease, Fuzhou 350001, Fujian, China

Received:2003-09-01 Revised:2003-10-12 Online:2004-01-26 Published:2020-11-16

摘要/Abstract

摘要： 脑利钠肽(BNP) 主要由心脏合成和分泌, 本质上是一种心脏神经激素, 只有在血容量增加和压力超负荷的情况下才反应性地从心室分泌。BNP 可作为心力衰竭的血浆标志物, 用于心力衰竭的诊断、治疗及预后评估。

关键词: 心力衰竭, 利钠肽, 脑, 诊断, 预后

Abstract: Brain natriuretic peptide (BNP) is synthesized and secreted chiefly from heart. It is a cardiac neurohormone specifically secreted from the ventricles in response to volume expansion and pressure overload. BNP is also a plasma marker for diagnosis, therapy and prognosis in patients with heart failure.

Key words: heart failure, brain natriuretic peptide, diagnosis, prognosis

中图分类号:

R541

陈协兴, 洪华山, 王一波. 脑利钠肽与心力衰竭的研究进展[J]. 中国临床药理学与治疗学, 2004, 9(1): 8-12.

CHEN Xie-Xing, HONG Hua-Shan, WANG Yi-Bo. Progress in research of brain natriuretic peptide and heart failure[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(1): 8-12.

参考文献

1 Grantham JA, Borgeson DD, Burnett JC.BNP:pathophysiological and potential therapeutic roles in acute congestive heart failure[J]. Am J physiol, 1997;272:R1077-83
2 Stein BC, Levin RI.Natriuretic peptides:phy siology, therapeutic potential, and risk stratification in ischemic heart disease[J]. Am Heart J, 1998;135:914-23
3 Nakagawa O, Ogawa Y, Itoh H, S Suga, Komatsu Y, Kishimoto I, et al. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy: evidence for brain natriuretic peptide as an “emergency” cardicac hormone against ventricular overload[J]. J Clin Invest,1995;96:1280-7
4 Maeda K, Tsutamota T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction[J]. Am Heart J, 1998;135:825-32
5 Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompsom SG, Pode-Wilsom PA, et al. Value of natriuretic peptide in assessment of patients with possible new heart failure in primary care[J]. Lancet, 1997;350:1349-53
6 Mcdonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrisou CE, et al. Biochemical detection of left ventricular systolic dysfunction[J]. Lancet, 1998;351:9-13
7 Maisel AS, Krishnaswamy P, Nowak RM, Mccovd J, Hollander JE, Duc P, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure[J]. N Engl J Med, 2002;347:161-7
8 Suzuki T, Yamaoki K, Nakajima O, Yamazaki T, yamada Y, Akioka H, et al. Screening for cardiac dysfunction in asymptomatic patients by measuring B-type natriuretic peptide levels[J]. Jpn Heart J, 2000;41:205-14
9 Bettencourt P, Ferreira A, Dias P, Castro A, Martins L, Cergueira-Ctomes M.Evaluation of brain natriuretic peptide in the diagnosis of heart failure[J]. Cardiology, 2000;93:19-25
10 Dao Q, Krishnaswamy P, Kazanegra R, Harrison A, Amirnovin R, Lenert L, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgentcare setting[J]. J Am Coll Cardiol, 2001;37:379-85
11 Morrison LK, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A.Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea[J]. J Am Coll Cardiol,2002;39:202-9
12 Harrison A, Morrison LK, Krishnaswamy P, Kazanegra R, Clopton P, Dao Q, et al. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea[J]. Ann Emerg Med, 2002;39:131-8
13 Berger R, Huelsman M, Strecker K, Bojic A, Moser P, Stanek B, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure[J]. Circulation,2002;105:2392-7
14 Richards AM, Nicholls MG, Yandle TG, Ikram H, Espiner EA, Turner JG, et al. Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction[J]. Heart, 1999;81:114-20
15 Tsutamoto T, Wada A, Maeda K, Hisanaga T, Mabuchi N, Hayashi M, et al. Plasma brain natriuretic peptide level as a biochemical mark of morbidity and mortality in patients with asymptomatic or symptomatic left ventricular dysfunction[J]. Eur Heart J, 1999;20:1799-807
16 Mills RM, Lejemtel TH, Hortou DP, Liang C, Lang R, Silver MA, et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure[J]. J Am Coll Cardiol, 1999;34:155-62
17 Elsener D, Muntze A, Kromer EP, Riegger GA.Effectiveness of endopeptidase inhibition (Candoxatril) in congestive heart failure[J]. Am J Cardiol, 1992;70:494-8
18 Hobbs RE, Miller LW, Bott-Silverman C, James KB, Rincon G, Grossbarb EB.Hemodynamic effects of a single intrenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy[J]. Am J Cardiol, 1996;78:896-901
19 Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM.Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations[J]. Lancet, 2000;355:1126-30
20 Cheng V, Kazanagra R, Garcia A, Lenert L, Krishnaswamy P, Gardetto N, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure:a pilot study[J]. J Am Coll Cardiol, 2001;37:386-91
21 Richards AM, Doughty R, Nicholls MG, Macmallsn S, Ikram H, Sharpe N, et al. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction[J]. Circutation, 1999;99:786-92
22 Struthers AD.How to use natriuretic peptide levels for diagnosis and prognosis[J]. Eur Heart J, 1999;20:1374-5

[1]	毛君, 荣玉, 李炎根, 熊登喜, 赵鹏, 查正江. 氟比洛芬酯在颅脑损伤患者镇痛治疗中的临床应用效果观察及安全性分析[J]. 中国临床药理学与治疗学, 2023, 28(9): 1056-1060.
[2]	王坤, 许佩佩, 周兰兰, 鲁晟. 人参皂苷Rg1调控Epac1/Rap1信号通路对缺血性脑卒中大鼠神经保护作用机制研究[J]. 中国临床药理学与治疗学, 2023, 28(7): 721-727.
[3]	郝潇, 赵美, 王文静, 张飞飞, 刘惠良, 党懿, 李树仁, 齐晓勇. 钠-葡萄糖共转运体2抑制剂在急性心肌梗死应用研究进展[J]. 中国临床药理学与治疗学, 2023, 28(7): 824-831.
[4]	李青华, 赵艳, 赵海港, 高朋飞, 徐炳欣. ABCB1 G2677T 基因多态性检测在缺血性脑卒中患者应用阿托伐他汀降脂治疗中的价值[J]. 中国临床药理学与治疗学, 2023, 28(6): 633-640.
[5]	秦文秀, 许军峰, 杨婷, 王坪霏. 丹参酮IIA治疗缺血性脑卒中后神经损伤的信号通路研究进展[J]. 中国临床药理学与治疗学, 2023, 28(6): 705-713.
[6]	徐渭, 陈峰, 叶志军. 金丝桃苷调节RhoA/ROCK信号通路对创伤性脑损伤大鼠的影响[J]. 中国临床药理学与治疗学, 2023, 28(4): 383-390.
[7]	石大伟, 郑晓永, 靳晓丹, 赵晓曼, 陈杰, 杜幸军. XPC基因多态性rs2228001对接受卡培他滨为基础辅助化疗的结直肠癌患者预后的影响[J]. 中国临床药理学与治疗学, 2023, 28(4): 391-399.
[8]	吴志勇, 刘兵荣, 李彬, 汤睿. 红细胞分布宽度对急性缺血性卒中静脉溶栓早期神经功能改善不良的预测作用[J]. 中国临床药理学与治疗学, 2023, 28(3): 307-314.
[9]	彭勇, 范剑峰, 熊旭华, 肖冬平, 高招波, 郑春华. 右旋糖酐铁片对合并铁缺乏的射血分数减低的心力衰竭患者的影响[J]. 中国临床药理学与治疗学, 2023, 28(2): 178-183.
[10]	黄凯歌, 许勤华, 王伟. 血糖、血钙对急性重症胰腺炎患者预后影响的交互作用及预测效能研究[J]. 中国临床药理学与治疗学, 2023, 28(11): 1227-1234.
[11]	陈玉林, 蒋虎刚, 王新强, 刘凯, 李应东, 安涛, 赵信科. 基于网络药理学和分子对接探讨芪参益心颗粒治疗射血分数保留型心力衰竭的作用机制[J]. 中国临床药理学与治疗学, 2023, 28(10): 1081-1092.
[12]	黄小明, 杜野, 林少明, 沈观乐. 呼吸道微生态对晚期非小细胞肺癌患者接受PD-1抑制剂单药治疗疗效影响的探索性研究[J]. 中国临床药理学与治疗学, 2023, 28(1): 66-74.
[13]	杨胜, 王德国. 沙库巴曲缬沙坦联合达格列净治疗射血分数减低型心力衰竭疗效及对血清cTnⅠ、BNP水平的影响[J]. 中国临床药理学与治疗学, 2022, 27(9): 1010-1015.
[14]	付虹, 田磊. 缺血性脑卒中伴高血压病患者个体化精准治疗的研究[J]. 中国临床药理学与治疗学, 2022, 27(8): 870-876.
[15]	梁美芳, 陈庆状, 杨沛群, 王勇. 基于真实世界的阿托伐他汀仿制药和原研药防治缺血性脑卒中/短暂性脑缺血发作的有效性和安全性比较[J]. 中国临床药理学与治疗学, 2022, 27(7): 785-792.